Combined measurement of H-FABP and MPO in the prognosis of non-ST elevation acute cornary syndromes
10.3969/j.issn.1673-4130.2016.02.007
- VernacularTitle:H-FABP和MPO联合应用对非ST段抬高急性冠状动脉综合征患者预后的评估
- Author:
Hongbo YU
;
Yang LIU
;
Junqing LUO
;
Xinguo LIU
;
Ming JIAN
;
Meiliang HUANG
;
Dan LUO
;
Xuefeng LI
- Publication Type:Journal Article
- Keywords:
acute coronary syndrome/diagnosis;
prognosis;
carrier proteins/blood;
fatty acids/blood;
peroxidase/blood
- From:
International Journal of Laboratory Medicine
2016;(2):159-160,163
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the prognosis value of heart‐type fatty‐acid binding protein(H‐FABP)and myeloperoxidase (MPO) in non‐ST elevation acute coronary syndromes(NSTE ACS) .Methods 181 NSTE ACS patients were divided into 4 groups according to the level of H‐FABP and MPO ,and the baselines of 4 groups such as gender ,age ,hypertension ,smoking ,body mass in‐dex ,diabetes mellitus ,hyperlipidemia were compared .The incidences of adverse cardiac events in 4 groups were compared after a 2 years′follow‐up .Results By multivariate COX regression adjustment for other risk factors ,the relative risk(RR) of H‐FABP for adverse cardiac events was 2 .023(95% CI:1 .029 -3 .987 ,P=0 .002) ,and MPO was (95% CI:2 .196 -5 .325 ,P< 0 .05) .The 2 years′follow‐up showed the incidence of adverse cardiac events in NSTE ACS patients with higher H‐FABP and MPO levels was higher than the NSTE ACS patients with one or two indicators of normal levels .Conclusion The combined application of H‐FABP and MPO could has clinical significance for the prognosis of patients with NSTE ACS .
